SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: contrarian who wrote (1480)2/6/1998 8:10:00 PM
From: Pseudo Biologist  Read Replies (2) of 1762
 
Contrarian,

Swarz's estimate changes are mentioned as "little noticed" in a recent article in the-street.com. The analyst is said to be still bullish about the product, but is also said to have revised the way in which he estimates the revenues will be split between Genentech and IDEC. Apparently, many have assumed that this was a more or less 50/50 deal, but it seems more complicated than that, and includes some "reimbursement for product and R&D" items from GNE to IDPH that will affect how much the latter ultimately gets from sales of Rituxan. Swarz's revisions, apparently, center on those items. Swarz's EPS numbers for 98 and 99 are way below of what the article cites as current First Call estimates (over $1 in 1999 for the latter source as per the reporter).

One last thing: I have not double checked the reporter's figures, but this piece has several parts. Only one of them deals with IDEC, in another part, having *nothing* to do with IDEC, the reporter's statements regarding estimates are at odds with what one can see in the Yahoo site, which uses Zacks. Unfortunately, Yahoo does not have 99 estimates at this point, and I am too lazy at the moment to look for other sources.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News